<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853723</url>
  </required_header>
  <id_info>
    <org_study_id>PRO08100148</org_study_id>
    <secondary_id>R01DK051081</secondary_id>
    <nct_id>NCT00853723</nct_id>
  </id_info>
  <brief_title>Comparison Study of PTHrP and PTH to Treat Osteoporosis</brief_title>
  <official_title>Comparison of 3 Month PTHrP(1-36) and PTH(1-34) on Post-Menopausal Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a three month comparison trial of standard dose parathyroid hormone (PTH) (1-34) and
      two different doses of Parathyroid Hormone-related Protein (PTHrP) (1-36). The investigators
      want to to demonstrate that daily subcutaneous injection of PTHrP (1-36) in postmenopausal
      women with osteoporosis stimulates bone formation to the same or greater degree than PTH
      (1-34) but with less bone resorption.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis is a metabolic bone disease characterized by low bone mass and structural
      deterioration of bone tissue. It results from failure of osteoblasts to form sufficient new
      bone, from an excessive rate of osteoclastic bone resorption, or from the combination of both
      processes. The resultant bone fragility leads to an increased susceptibility to fractures,
      especially of the hip, spine and wrist. There is an increased mortality rate following both
      hip and vertebral fractures, and the presence of one fracture is a potent risk factor for
      future fractures. This leads to a decline in the quality of life and an associated loss of
      independence among the millions of individuals in the United States and worldwide afflicted
      with the disease. There is an additional population at an increased risk for fractures due to
      a less severe loss of bone mass, known as osteopenia (1). Already ten million individuals in
      the United States are estimated to have the disease and thirty four million more are at
      increased risk due to low bone mass (1).

      Approved pharmacological treatments for postmenopausal osteoporosis include two classes of
      drugs: the antiresorptive and the anabolics (2). The antiresorptive include estrogen,
      calcitonin, selective estrogen receptor modulators, and bisphosphonates. The antiresorptive
      medications prevent bone loss by inhibiting both osteoclastic bone resorption and formation,
      by slowing bone turnover, and by allowing for increased mineralization of osteoid (2). The
      increase in bone mineral density from the antiresorptive agents is generally reported to be
      in the range of 2-8% over 1-7 years (3-7).

      There is only one anabolic agent that is presently approved by the FDA for treatment for
      osteoporosis: parathyroid hormone, PTH (1-34), or teriparatide. PTH(1-34) was approved by the
      FDA in 2002 and it acts by increasing bone density by stimulating the PTH-1 receptor. This
      induces an increase in osteoblast mediated bone formation and osteoclast mediated bone
      resorption. Daily subcutaneous PTH is anabolic as there is stimulation of bone formation to a
      greater extent than bone resorption. The overall net result of biosynthetic PTH (1-34) is an
      increase in bone mineral density and a decrease in fractures (8). Daily PTH(1-34) treatment
      has been shown to effectively reduce the risk of both vertebral and nonvertebral fractures.
      Measurements of bone mineral density (BMD) of the lumbar spine (LS) resulted in an increase
      in bone density of 9 percent when compared to placebo (9). A daily 20 microgram dose of
      subcutaneous PTH(1-34) reduced the risk of getting two or more vertebral fractures by 77%,
      and the risk of at least one moderate or severe fracture was reduced by 90 and 78%
      respectively (9). Additionally, one vertebral fracture was prevented for every 12 patient
      years of treatment, and women were 35% less likely to have one or more new nonvertebral
      fragility fractures (9).

      Parathyroid hormone-related protein or PTHrP is a protein peptide that was first isolated in
      1987 as the factor responsible for the syndrome of humoral hypercalcemia of malignancy (HHM)
      (10-14). PTHrP is found in almost every tissue and cell type in the body, and appears to
      regulate cellular proliferation, survival, and differentiation in normal tissue as well as in
      malignancies (15-16). As the name implies, PTHrP is similar to PTH. Both peptides bind to the
      same receptor, PTH-1 R, and activate downstream signaling pathways causing similar post
      receptor effects (17).

      Since PTH is a potent anabolic agent, we hypothesize that PTHrP may act in an anabolic
      fashion as well. We are seeking to demonstrate in this study that PTHrP acts as an anabolic
      agent in the treatment of osteoporosis with similar or better efficacy than PTH in respect to
      bone formation but with less bone resorption and fewer side effects, such as hypercalcemia.

      The current studies are a sequel to initial phase 1 trials assessing the efficacy and safety
      of daily subcutaneous injection of PTHrP on the human skeleton. Previous studies have
      demonstrated that a single daily injection of ~ 400 mcg/day of PTHrP (1-36) in postmenopausal
      women on estrogen with osteoporosis led to a 4.7% increase in lumbar spine bone mineral
      density (BMD) after three months and all subjects were free of hypercalcemia or other adverse
      effects (18). In contrast with PTH, the doses of PTHrP are much larger, yet well-tolerated,
      and the increments in spine BMD are large and rapid with some subjects showing increases in
      spine BMD of 6-8% in as soon as three months in studies done thus far (18). PTHrP appears to
      selectively stimulate bone formation without stimulating bone resorption (18). This exciting
      observation may point towards PTHrP being a pure skeletal anabolic agent (21). Preliminary
      data analysis from a more recent three week dose escalation trial indicates demonstrates that
      the dose of 500 mcg/day of PTHrP causes 38% increase in P1NP and a 20% decrease in CTX
      indicating far greater bone formation than bone resorption with no hypercalcemia. At 625
      mcg/day there were similar increases in P1NP with hypercalcemia in only 10% of subjects and
      hypercalcuria in 20%. In contrast in subjects receiving 750 mcg/day 50% developed
      hypercalcemia requiring early termination. The P1NP and CTX data from the three week dose
      escalation trial was used for both determining dose and sample size calculations for this
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procallagen-1 Amino-terminal Peptide (P1NP)</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Carboxy-terminal Telopeptides of Collagen-1 (CTX)</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Bone Mineral Density of the Lumbar Spine.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Bone Mineral Density of the Total Hip.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Bone Mineral Density of the Femoral Neck.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Bone Mineral Density of the Forearm.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Bone Mineral Density of the Distal 1/3 Radius.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Serum Calcium (mg/dl)</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Phosphorous</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 Hour Urine Calcium</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,25 Vitamin D</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional Excretion of Calcium</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
    <description>(Serum Creatinine X Urine Calcium)/(Serum Calcium X Urine Creatinine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tubular Maximum for Phosphorous/Glomerular Filtration Rate (TMP/GFR)</measure>
    <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
    <description>Fractional tubular reabsorption of phosphate (TRP) = 1-{(U phos/P phos) x ( P creat/U creat)} if TRP &lt; or = 0.86 then TMP/GFR = TRP x P phos if TRP &gt; 0.86 then TMP/GFR = 0.3 x TRP/{1-(0.8 x TRP)} x P phos
U= urine, P = plasma</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>PTHrP 400 mcg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTHrP 600 mcg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTH 20 mcg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parathyroid hormone related protein (1-36)</intervention_name>
    <description>PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months</description>
    <arm_group_label>PTHrP 400 mcg/day</arm_group_label>
    <other_name>PTHrP (1-36)</other_name>
    <other_name>PTHrP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parathyroid hormone related protein(1-36)</intervention_name>
    <description>PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months</description>
    <arm_group_label>PTHrP 600 mcg/day</arm_group_label>
    <other_name>PTHrP (1-36)</other_name>
    <other_name>PTHrP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parathyroid hormone (1-34)</intervention_name>
    <description>PTH(1-34)20 micrograms subcutaneously administered daily for 3 months</description>
    <arm_group_label>PTH 20 mcg/day</arm_group_label>
    <other_name>PTH(1-34)</other_name>
    <other_name>Teriparatide (brand name: Forteo)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  45 - 75 year old Caucasian, Hispanic or Asian women

          -  one year post-menopausal if older than 50 years

          -  three years post-menopausal if between the ages of 45 - 50 years

          -  body mass index less than or equal to 30

          -  T-scores on screening Dual X-Ray Absorbiometry (DXA) scan between - 2.0 to - 4.5 of
             lumbar spine or hip

          -  have at lease two spinal vertebrae evaluable by DXA analysis

        Exclusion Criteria:

          -  bisphosphonate therapy within the last two years

          -  estrogen replacement hormones or SERMS within last one year

          -  no more than one week of PTHrP, PTH, or an analog of PTH within the last year

          -  an atraumatic bone fracture within the last 6 months

          -  significant or active diseases of any organ system

          -  history of malignancy

          -  anemia with a hematocrit less than 34%

          -  significant drug or alcohol abuse

          -  having received any investigational drug within the last 90 days

          -  taking any medication that may interfere with skeletal metabolism, such as
             phenobarbital, dilantin, glucocorticoids, and hydrochlorathiazide

          -  abnormal screening labs including serum Ca greater than 10.5 g/dl, 25 hydroxy vitamin
             D less than 20 ng/ml or PTH greater than 65 pg/ml

          -  African-Americans for this particular study - although future studies are planned
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mara J Horwitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Clinical &amp; Translational Research Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicalresearch.pitt.edu/</url>
    <description>University of Pittsburgh's clinical research study website</description>
  </link>
  <reference>
    <citation>http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed August 22, 2008</citation>
  </reference>
  <reference>
    <citation>Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt DC, Rosen E, Majumdar S, Rosen CJ; PTH Once-Weekly Research (POWR) Group. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab. 2008 Jun;93(6):2166-72. doi: 10.1210/jc.2007-2781. Epub 2008 Mar 18.</citation>
    <PMID>18349061</PMID>
  </reference>
  <reference>
    <citation>Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA. 1996 Nov 6;276(17):1389-96.</citation>
    <PMID>8892713</PMID>
  </reference>
  <reference>
    <citation>Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995 Nov 30;333(22):1437-43.</citation>
    <PMID>7477143</PMID>
  </reference>
  <reference>
    <citation>Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997 Dec 4;337(23):1641-7.</citation>
    <PMID>9385122</PMID>
  </reference>
  <reference>
    <citation>Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000 Sep;109(4):267-76.</citation>
    <PMID>10996576</PMID>
  </reference>
  <reference>
    <citation>Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab. 2000 May;85(5):1895-900.</citation>
    <PMID>10843171</PMID>
  </reference>
  <reference>
    <citation>Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-41.</citation>
    <PMID>11346808</PMID>
  </reference>
  <reference>
    <citation>Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med. 1980 Dec 11;303(24):1377-83.</citation>
    <PMID>6253785</PMID>
  </reference>
  <reference>
    <citation>Stewart AF, Vignery A, Silverglate A, Ravin ND, LiVolsi V, Broadus AE, Baron R. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab. 1982 Aug;55(2):219-27.</citation>
    <PMID>7085851</PMID>
  </reference>
  <reference>
    <citation>Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med. 2000 Jan 20;342(3):177-85. Review.</citation>
    <PMID>10639544</PMID>
  </reference>
  <reference>
    <citation>Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ, Stewart AF. Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N Engl J Med. 1988 Sep 1;319(9):556-63. Review.</citation>
    <PMID>3043221</PMID>
  </reference>
  <reference>
    <citation>Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff JJ, Yang KH, Vasavada RC, Weir EC, Broadus AE, Stewart AF. Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev. 1996 Jan;76(1):127-73. Review.</citation>
    <PMID>8592727</PMID>
  </reference>
  <reference>
    <citation>Orloff JJ, Reddy D, de Papp AE, Yang KH, Soifer NE, Stewart AF. Parathyroid hormone-related protein as a prohormone: posttranslational processing and receptor interactions. Endocr Rev. 1994 Feb;15(1):40-60. Review.</citation>
    <PMID>8156938</PMID>
  </reference>
  <reference>
    <citation>Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9.</citation>
    <PMID>12679445</PMID>
  </reference>
  <reference>
    <citation>Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003 Feb;88(2):569-75.</citation>
    <PMID>12574182</PMID>
  </reference>
  <reference>
    <citation>Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res. 2000 Aug;15(8):1517-25.</citation>
    <PMID>10934650</PMID>
  </reference>
  <reference>
    <citation>Dean T, Vilardaga JP, Potts JT Jr, Gardella TJ. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol. 2008 Jan;22(1):156-66. Epub 2007 Sep 13.</citation>
    <PMID>17872377</PMID>
  </reference>
  <reference>
    <citation>Bisello A, Horwitz MJ, Stewart AF. Parathyroid hormone-related protein: an essential physiological regulator of adult bone mass. Endocrinology. 2004 Aug;145(8):3551-3.</citation>
    <PMID>15265822</PMID>
  </reference>
  <reference>
    <citation>Horwitz MJ, Tedesco MB, Sereika SM, Garcia-Ocaña A, Bisello A, Hollis BW, Gundberg C, Stewart AF. Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. Osteoporos Int. 2006 Feb;17(2):225-30. Epub 2005 Sep 7.</citation>
    <PMID>16151606</PMID>
  </reference>
  <reference>
    <citation>FORTEO (package insert). Indianapolis, IN: Eli Lilly and Company; 2008.</citation>
  </reference>
  <reference>
    <citation>Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab. 2007 Sep;92(9):3535-41. Epub 2007 Jul 3.</citation>
    <PMID>17609307</PMID>
  </reference>
  <reference>
    <citation>McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005 Aug 8-22;165(15):1762-8. Erratum in: Arch Intern Med. 2005 Oct 10;165(18):2120.</citation>
    <PMID>16087825</PMID>
  </reference>
  <reference>
    <citation>Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, Efstathiadou Z, Kita M, Avramidis A. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. Int J Clin Pract. 2008 Jun;62(6):919-24. doi: 10.1111/j.1742-1241.2008.01768.x. Epub 2008 Apr 17.</citation>
    <PMID>18422590</PMID>
  </reference>
  <reference>
    <citation>Tashjian AH Jr, Gagel RF. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res. 2006 Mar;21(3):354-65. Epub 2005 Nov 11. Review.</citation>
    <PMID>16491282</PMID>
  </reference>
  <reference>
    <citation>Horwitz MJ, Stewart Af. Humoral hypercalcemia of malignancy. In: Favus MF (ed.) Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed. American Society for Bone and Mineral Research, Washington, DC, USA, pp. 246-250:2003.</citation>
  </reference>
  <reference>
    <citation>Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials. 1981 Jun;2(2):93-113.</citation>
    <PMID>7273794</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <results_first_submitted>July 15, 2015</results_first_submitted>
  <results_first_submitted_qc>January 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2016</results_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Mara Horwitz</investigator_full_name>
    <investigator_title>Associate Professor, University of Pittsburgh School of Medicine</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>post-menopausal</keyword>
  <keyword>bone anabolic agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PTHrP 400 mcg/Day</title>
          <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 400 micrograms / day for 3 months</description>
        </group>
        <group group_id="P2">
          <title>PTHrP 600 mcg/Day</title>
          <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 600 micrograms / day for 3 months</description>
        </group>
        <group group_id="P3">
          <title>PTH 20 mcg/Day</title>
          <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone (PTH) 1-34, 20 micrograms / day for 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Postmenopausal women age 45-75 with osteoporosis or low bone density</population>
      <group_list>
        <group group_id="B1">
          <title>PTHrP 400 mcg/Day</title>
          <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 400 micrograms / day for 3 months</description>
        </group>
        <group group_id="B2">
          <title>PTHrP 600 mcg/Day</title>
          <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 600 micrograms / day for 3 months</description>
        </group>
        <group group_id="B3">
          <title>PTH 20 mcg/Day</title>
          <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone (PTH) 1-34, 20 micrograms / day for 3 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" spread="5.22"/>
                    <measurement group_id="B2" value="61.2" spread="5.10"/>
                    <measurement group_id="B3" value="62.4" spread="5.26"/>
                    <measurement group_id="B4" value="61.4" spread="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Procallagen-1 Amino-terminal Peptide (P1NP)</title>
        <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 400 micrograms / day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 600 micrograms / day for 3 months</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone (PTH) 1-34, 20 micrograms / day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Procallagen-1 Amino-terminal Peptide (P1NP)</title>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.54" spread="5.09"/>
                    <measurement group_id="O2" value="23.51" spread="7.04"/>
                    <measurement group_id="O3" value="60.67" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.89" spread="5.7"/>
                    <measurement group_id="O2" value="83.14" spread="12.48"/>
                    <measurement group_id="O3" value="97.27" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.71" spread="5.78"/>
                    <measurement group_id="O2" value="87.39" spread="22.24"/>
                    <measurement group_id="O3" value="125.46" spread="17.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.07" spread="12.12"/>
                    <measurement group_id="O2" value="84.09" spread="20.57"/>
                    <measurement group_id="O3" value="171.49" spread="26.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>An equivalence test of means for the percentage change in PINP and CTX using two one-sided tests applied to data from the parallel group design with a sample size of 31 in the PTH(1-34) group and 62 in the combined PTHrP(1-36) group achieved 80% power at 2.5% significant level for two-sided hypothesis testing (adjusted for the hypothesis testing at two key endpoints).</non_inferiority_desc>
            <p_value>&lt;0.0005</p_value>
            <p_value_desc>The reported p-value corresponds with percent change from baseline by day 15 in all three arms.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Bone Mineral Density of the Lumbar Spine.</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 400 micrograms / day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 600 micrograms / day for 3 months</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone (PTH) 1-34, 20 micrograms / day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Bone Mineral Density of the Lumbar Spine.</title>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.49"/>
                    <measurement group_id="O2" value="1.52" spread="0.61"/>
                    <measurement group_id="O3" value="2.17" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The reported p-value corresponds with percent change from baseline in all Arms/groups.</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>The threshold for stasistical significance was p=0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Carboxy-terminal Telopeptides of Collagen-1 (CTX)</title>
        <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 400 micrograms / day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 600 micrograms / day for 3 months</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone (PTH) 1-34, 20 micrograms / day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Carboxy-terminal Telopeptides of Collagen-1 (CTX)</title>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.40" spread="7.19"/>
                    <measurement group_id="O2" value="10.25" spread="10.66"/>
                    <measurement group_id="O3" value="4.87" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="10.65"/>
                    <measurement group_id="O2" value="9.59" spread="16.49"/>
                    <measurement group_id="O3" value="13.89" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13" spread="7.93"/>
                    <measurement group_id="O2" value="14.38" spread="15.89"/>
                    <measurement group_id="O3" value="52.98" spread="22.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.65" spread="14.86"/>
                    <measurement group_id="O2" value="25.65" spread="11.75"/>
                    <measurement group_id="O3" value="92.46" spread="18.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>An equivalence test of means for the percentage change in PINP and CTX using two one-sided tests applied to data from the parallel group design with a sample size of 31 in the PTH(1-34) group and 62 in the combined PTHrP(1-36) group achieved 80% power at 2.5% significant level for two-sided hypothesis testing (adjusted for the hypothesis testing at two key endpoints).</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The reported p-value corresponds with percent change from baseline at Day 60 and at Day 90 for the PTH group and at day 90 for the PTHrP 400 and PTHrP 600 groups .</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Bone Mineral Density of the Total Hip.</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 400 micrograms / day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 600 micrograms / day for 3 months</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone (PTH) 1-34, 20 micrograms / day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Bone Mineral Density of the Total Hip.</title>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.29"/>
                    <measurement group_id="O2" value="0.72" spread="0.30"/>
                    <measurement group_id="O3" value="0.54" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The reported p-value corresponds with percent change from baseline in PTHrP 400 and 600 groups.</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>The threshold for stastistical significance was p=0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Bone Mineral Density of the Femoral Neck.</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 400 micrograms / day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 600 micrograms / day for 3 months</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone (PTH) 1-34, 20 micrograms / day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Bone Mineral Density of the Femoral Neck.</title>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.41"/>
                    <measurement group_id="O2" value="0.54" spread="0.48"/>
                    <measurement group_id="O3" value="0.61" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The reported p-value corresponds with percent change from baseline in the PTHrP 400 group</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>The threshold for stastistical significance was p=0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Bone Mineral Density of the Forearm.</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 400 micrograms / day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 600 micrograms / day for 3 months</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone (PTH) 1-34, 20 micrograms / day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Bone Mineral Density of the Forearm.</title>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.61"/>
                    <measurement group_id="O2" value="-0.99" spread="0.78"/>
                    <measurement group_id="O3" value="-0.97" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes.</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The reported p-value corresponds with percent change from baseline in all Arms/groups</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>The threshold for statistical signifcance was p=0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Bone Mineral Density of the Distal 1/3 Radius.</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 400 micrograms / day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 600 micrograms / day for 3 months</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone (PTH) 1-34, 20 micrograms / day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Bone Mineral Density of the Distal 1/3 Radius.</title>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.54"/>
                    <measurement group_id="O2" value="-0.34" spread="0.96"/>
                    <measurement group_id="O3" value="-0.82" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes.</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The reported p-value corresponds with percent change from baseline in all Arms/groups</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>The threshold for statistical significance was p=0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Serum Calcium (mg/dl)</title>
        <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Serum Calcium (mg/dl)</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.48" spread="0.06"/>
                    <measurement group_id="O2" value="9.51" spread="0.06"/>
                    <measurement group_id="O3" value="9.49" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.95" spread="0.09"/>
                    <measurement group_id="O2" value="9.87" spread="0.09"/>
                    <measurement group_id="O3" value="9.57" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.73" spread="0.09"/>
                    <measurement group_id="O2" value="9.67" spread="0.06"/>
                    <measurement group_id="O3" value="9.55" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.71" spread="0.07"/>
                    <measurement group_id="O2" value="9.61" spread="0.06"/>
                    <measurement group_id="O3" value="9.58" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90, time 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.56" spread=".07"/>
                    <measurement group_id="O2" value="9.45" spread="0.07"/>
                    <measurement group_id="O3" value="9.44" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90, time 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.90" spread="0.08"/>
                    <measurement group_id="O2" value="9.76" spread="0.07"/>
                    <measurement group_id="O3" value="9.75" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 90, time 6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.90" spread="0.07"/>
                    <measurement group_id="O2" value="9.81" spread="0.10"/>
                    <measurement group_id="O3" value="9.78" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes.</non_inferiority_desc>
            <p_value>&lt;0.0005</p_value>
            <p_value_desc>The reported p-value corresponds to change from baseline at Day 15 and 30 in the PTHrP 400 group and at Day 15 in the PTHrP 600 group</p_value_desc>
            <method>F-test, one way analysis of variance</method>
            <method_desc>The threshold for statistical significance was p=0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Phosphorous</title>
        <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Phosphorous</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.07"/>
                    <measurement group_id="O2" value="3.93" spread="0.08"/>
                    <measurement group_id="O3" value="4.09" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" spread="0.07"/>
                    <measurement group_id="O2" value="3.68" spread="0.08"/>
                    <measurement group_id="O3" value="4.13" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="0.09"/>
                    <measurement group_id="O2" value="3.71" spread="0.09"/>
                    <measurement group_id="O3" value="4.19" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="0.07"/>
                    <measurement group_id="O2" value="3.97" spread="0.08"/>
                    <measurement group_id="O3" value="4.28" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.05" spread="0.09"/>
                    <measurement group_id="O2" value="3.98" spread="0.07"/>
                    <measurement group_id="O3" value="4.10" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The reported p-value corresponds to PTH group on Day 60 compared to the PTHrP 400</p_value_desc>
            <method>F-test, one way analysis of variance</method>
            <method_desc>The threshold for statistical significance was p=0.05</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes.</non_inferiority_desc>
            <p_value>&lt;0.005</p_value>
            <p_value_desc>The reported p-value corresponds to the PTH group on Day 30 compared to the PTHrP 400 group and Day 60 compared to the PTHRp 600 group</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>The threshold for statistical significance was p=0.05</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes.</non_inferiority_desc>
            <p_value>&lt;0.0005</p_value>
            <p_value_desc>The reported p-value correspond to the PTH group on Day 15 compared to the PTHrP 400 group and Day 15 and 30 compared to the PTHrP 600 group.</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>The threshold for statistical significance was p=0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24 Hour Urine Calcium</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.</description>
          </group>
        </group_list>
        <measure>
          <title>24 Hour Urine Calcium</title>
          <units>mg/gm creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.37" spread="14.08"/>
                    <measurement group_id="O2" value="213.07" spread="16.22"/>
                    <measurement group_id="O3" value="209.99" spread="14.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.46" spread="22.72"/>
                    <measurement group_id="O2" value="235.25" spread="20.34"/>
                    <measurement group_id="O3" value="232.48" spread="17.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes.</non_inferiority_desc>
            <p_value>&lt;0.005</p_value>
            <p_value_desc>The reported p-value corresponds to the increase from baseline to D90 in the PTHrP 400 group.</p_value_desc>
            <method>F-test, one way analysis of variance</method>
            <method_desc>the threshold for statistical significance was p=0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1,25 Vitamin D</title>
        <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.</description>
          </group>
        </group_list>
        <measure>
          <title>1,25 Vitamin D</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.06" spread="3.24"/>
                    <measurement group_id="O2" value="42.49" spread="2.20"/>
                    <measurement group_id="O3" value="42.51" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.92" spread="5.65"/>
                    <measurement group_id="O2" value="63.07" spread="4.71"/>
                    <measurement group_id="O3" value="65.25" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.04" spread="4.65"/>
                    <measurement group_id="O2" value="65.15" spread="3.71"/>
                    <measurement group_id="O3" value="67.29" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.85" spread="4.40"/>
                    <measurement group_id="O2" value="57.02" spread="4.07"/>
                    <measurement group_id="O3" value="58.15" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.36" spread="4.34"/>
                    <measurement group_id="O2" value="55.08" spread="4.20"/>
                    <measurement group_id="O3" value="53.73" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The reported p value corresponds to an increased from baseline at all time points in all Arms/groups as well as to the increase in the in the PTHrP 400 group at Day 60 and 90 compared to the PTHrP 600 and PTH groups .</p_value_desc>
            <method>F-test, one way analysis of variance</method>
            <method_desc>the threshold for statistical significance was p=0.05</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes</non_inferiority_desc>
            <p_value>&lt;0.005</p_value>
            <p_value_desc>The reported p-value corresponds to the comparison of the PTHrP 400 group at Day 15 to the PTHrP 600 and PTH groups</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>The threshold for statistical significance was p=0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fractional Excretion of Calcium</title>
        <description>(Serum Creatinine X Urine Calcium)/(Serum Calcium X Urine Creatinine)</description>
        <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Excretion of Calcium</title>
          <description>(Serum Creatinine X Urine Calcium)/(Serum Calcium X Urine Creatinine)</description>
          <units>% excreted</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="0.21"/>
                    <measurement group_id="O2" value="2.71" spread="0.24"/>
                    <measurement group_id="O3" value="2.30" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" spread="033"/>
                    <measurement group_id="O2" value="4.18" spread="0.39"/>
                    <measurement group_id="O3" value="2.55" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="0.34"/>
                    <measurement group_id="O2" value="3.74" spread="0.27"/>
                    <measurement group_id="O3" value="2.92" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="0.34"/>
                    <measurement group_id="O2" value="2.89" spread="0.28"/>
                    <measurement group_id="O3" value="2.95" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" spread="0.25"/>
                    <measurement group_id="O2" value="2.89" spread="0.27"/>
                    <measurement group_id="O3" value="3.37" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The reported p-value corresponds to an increase compared to baseline in the PTHrP 600 group at D15 and D30</p_value_desc>
            <method>F-test, one way analysis of variance</method>
            <method_desc>The threshold for stastistical significance was p=0.05</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate.</non_inferiority_desc>
            <p_value>&lt;0.005</p_value>
            <p_value_desc>the reported p-value corresponds to change from baseline in the PTHrP 400 group at Day 15,30, 60 and 90 and the PTH group at day 90.</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>the threshold for statistical significance was p=0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tubular Maximum for Phosphorous/Glomerular Filtration Rate (TMP/GFR)</title>
        <description>Fractional tubular reabsorption of phosphate (TRP) = 1-{(U phos/P phos) x ( P creat/U creat)} if TRP &lt; or = 0.86 then TMP/GFR = TRP x P phos if TRP &gt; 0.86 then TMP/GFR = 0.3 x TRP/{1-(0.8 x TRP)} x P phos
U= urine, P = plasma</description>
        <time_frame>Baseline, Day 15, Day 30, Day 60, Day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PTHrP 400 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.</description>
          </group>
          <group group_id="O2">
            <title>PTHrP 600 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.</description>
          </group>
          <group group_id="O3">
            <title>PTH 20 mcg/Day</title>
            <description>Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.</description>
          </group>
        </group_list>
        <measure>
          <title>Tubular Maximum for Phosphorous/Glomerular Filtration Rate (TMP/GFR)</title>
          <description>Fractional tubular reabsorption of phosphate (TRP) = 1-{(U phos/P phos) x ( P creat/U creat)} if TRP &lt; or = 0.86 then TMP/GFR = TRP x P phos if TRP &gt; 0.86 then TMP/GFR = 0.3 x TRP/{1-(0.8 x TRP)} x P phos
U= urine, P = plasma</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="0.11"/>
                    <measurement group_id="O2" value="3.71" spread="0.11"/>
                    <measurement group_id="O3" value="3.96" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" spread="0.14"/>
                    <measurement group_id="O2" value="3.47" spread="0.15"/>
                    <measurement group_id="O3" value="4.18" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="0.14"/>
                    <measurement group_id="O2" value="3.61" spread="0.14"/>
                    <measurement group_id="O3" value="4.03" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="0.14"/>
                    <measurement group_id="O2" value="3.84" spread="0.13"/>
                    <measurement group_id="O3" value="4.28" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="0.11"/>
                    <measurement group_id="O2" value="3.90" spread="0.12"/>
                    <measurement group_id="O3" value="4.00" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The reported p-value corresponds the PTH group on Day 15 compared to the PTHrP 400 group and to the PTHrP 600 group at Day 30 and Day 60</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>The threshold for statistical significance was p=0.05</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate.</non_inferiority_desc>
            <p_value>&lt;0.0005</p_value>
            <p_value_desc>Thre reported p-value correspond to the PTH group compared to the PTHrp 600 group at day 15</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>the threshold for statistical significance was p=0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse event data was collected at each study visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>PTHrP 400 mcg/Day</title>
          <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.</description>
        </group>
        <group group_id="E2">
          <title>PTHrP 600 mcg/Day</title>
          <description>Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.</description>
        </group>
        <group group_id="E3">
          <title>PTH 20 mcg/Day</title>
          <description>Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatologic</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was not double-blinded. There was no placebo group in this study. Subjects had higher than anticipated calcium intake and baseline vitamin D levels.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mara J Horwitz</name_or_title>
      <organization>UPittsburgh</organization>
      <phone>4126922848</phone>
      <email>horwitz@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

